In conclusion, our data suggest that the CCR4/CCL17-CCL22 axis might be involved in metabolic and vascular alterations associated with human morbid obesity, and that its pharmacological modulation may represent a promising target for the treatment of obesity-related cardiovascular and metabolic complications. Here, CCR4 is linked to obesity disorder.